The association between respiratory syncytial virus infection and reactive airway disease.
Evidence has been accumulating that respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in infants may be linked to subsequent development of reactive airway disease (RAD) in childhood, and therefore research into the prevention of RSV LRTI may have important implications for the prevention of RAD. This article reviews the epidemiological evidence linking RSVand RAD and some ofthe theories concerning cellular and molecular mechanisms of post-viral airway inflammation in order to understand how RSV prophylaxis may assist in reducing the occurrence of RSV LRTI and RAD.
Piedimonte
G
G
Department of Pediatrics, University of Miami School of Medicine, FL, USA. gpiedimo@med.miami.edu
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage; D001249:Asthma / Q000517:prevention & control / Q000821:virology*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000150:complications* / Q000517:prevention & control; D018113:Respiratory Syncytial Virus, Human / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D014614:Vaccines, Synthetic; D000069455:Palivizumab